Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapablursen in Non-Transfusion Dependent β-Thalassemia Intermedia
NCT04059406Phase 2Terminated
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Small Interfering RNA (siRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of sapablursen in beta-thalassemia intermedia, sponsored by Ionis Pharmaceuticals. Started Sep 2020; status: terminated.
02
Drugs
sapablursen
03
Conditions
beta-thalassemia intermedia
Beyond the preview
Go deeper on NCT04059406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059406.